R.J. Tesi
the introduce my year the programs. pandemic of updates the Moss which we and remarkable takeaways for we would carefully to our before our public development Then as lines impact everyone results, our business, from lives. At programs will [Lyndon]. INmune acknowledge financial INmune discuss David our to operational and arrange you, Thanks today. strategy highlights Bio, first milestone remiss joining be key coronavirus, market our speed the I share COVID-XX I we upcoming for on is first, a at are open company. not then Bio the on to capital clinical our Thank remarks Q&A. changing assessing will But
a impact rescheduled treating although to shall optimistic Today, AACR just On converted two the to and meeting. Diseases that say COVID-XX the may canceled manageable, in a have in The was measured, neutralizing platform Vienna coronavirus population. in the major or related Annual worse infection not and complications yesterday, Alzheimer's more, we directly. is or is Often, note, San it Many virtual does but role change the meetings. Diego elderly in Meeting medical Parkinson's a inflammation. of relate our a vulnerable DN-TNF was to
immunology understand understands treating Bio unique disease are inflammation we INmune are that we risk program. high of in Alzheimer's this population. group They and the an
We the assessing are this will plans can in if Once to and complete, national emergency. communicate play to you. our we role, we assessment what response is actively
three eventful those year and or is that cancer cancer two was the year developments XXXX including disease and with the Now now Company. NASH. five a year, onto eight our significant Alzheimer's cancer programs with We of three drug and three programs dedicated busy platforms started with and treatment the last across one the platforms for to drug across two in
platforms. disease report X our been and the NASH therapeutic for XXXX busy programs Alzheimer's has Phase The in progress results ongoing in work sets program. AML, programs where Phase a plan cancer XXXX the the for Our form and initiate of high of ovarian MDS, X oncology in foundation the risk two to we a X Phase stage and
the makes The cells own the first platform NK that patient's own patient's priming platform cells. better is NK our natural I killer emphasize and cell
demyelination the currently DN-TNF is party negative TNF in infection. that generation cancer dominant TNF. platform, the The second of programs and cannot selective response different promoting the inhibitor preclinical NASH. that DN-TNF novel next biological the the against The that of show platform put inhibitors. INBXX cancer Alzheimer's TNF data and I overemphasize LIVNate these the To extensive the and platform TNF less bad immune for generates a platform TNF XPro causes for DN-TNF approved third is function three non-selective fact immunosuppression neutralizes differences while bad for good for unique and the most improves disease, from perspective, platform of the very
platform patient. others, of to with that in the inhibitors, TNF occur namely A initiate currently the DN-TNF demyelination, very consequences allows areas like therapeutic where in for current, INmune off suppressors immune limits and but Bio TNF disastrous has not set those biologic programs unique first-generation approved and Humira cause to Embrel are the oncology our an and of characteristic the attributes that immunosuppression good inhibitors did
CNS indications were the patient's may disease. demyelination worsen
for We our emphasize to cancer February have I support the and Company had The INBXX Xth. review IPO and findings you platform. immune-oncology I in many NK and with these INmune programs publications them. two to on website platform, our cancer for encourage DN-TNF many Bio the INKmune, completed
that that into in and NASH. Alzheimer's diseases like are programs did both involve and matured areas have cancer we in Now, malignant not disease five therapeutic
with Alzheimer's I biomarker a were into $X That targeting X patient on we our award will after into last this neuroinflammation, move enrolled flagship first XProXXXX advance IPO XXXX, grant unique for week now our the trial million our Phase year to X a highlight continues forward the directed with disease. the and cloud called Phase a One awarded February of Alzheimer's trial. program clinical association therapy design. treatment program the dysfunction XProXXXX synaptic from to trial starting novel
and affects the studying in program disease. the Alzheimer's patients to disease. with XProXXXX the neurodegeneration two safety neuroinflammation, is disease to ongoing symptoms Alzheimer's Alzheimer's devastating first decreases show a to is the first, disease. addition XProXXXX that XPro of drug is in in designed this neuroinflammation In assessing step of decreases The patients, safely step as demonstrate This trial
Phase The second with the cognitive patients and a drug disease demonstrate, in X or step, decline. by clinical if can trial prevent larger decreasing Alzheimer's slow will neuroinflammation longer
prevents from cause synaptic strategies and this To differs and targeting elements approach cell the tangles nerve improves preclinical plaques of tau a the be dysfunction. synaptic pathologic models, therapeutic believe any dysfunction. key clear, of death death We cell dementia amyloid of respectively. In XPro nerve and or
year clinical We planning have Phase already expect the we the begun program. trial results to the report the of second and half in X
positive Phase the program X assuming data Our initiate to quickly. goal, is
more that with deadly. both is the the in to with Association, X and Americans the is in that living currently billion debilitating There know roughly cause United cost triple Alzheimer than will double we States future. disease will the Alzheimer's leading may the all the Association no are and near change XXXX. disease, death number more by modifying costing million The the almost this than You forecast sixth think of According in that disease Alzheimer's XXXX. Alzheimer's but $XXX therapies,
dose first. patients was or of our it who X escalation announced tumors was as multiple had program and or an the and INBXX trial TNF. a in an solid it pharmacodynamic guess one name into label previous DN-TNF trial had be solid in program It the the used with in Moving soluble effect patients well inflammatory was of our to downstream maybe up actually dose with completed of patients the in goals. the depends safe I The immuno-oncology tolerated demonstrated trial therapy is a regulation open INBXX because a of Phase in failed upcoming last lines its advanced met first on all it of decrease cytokines, went Phase tumors dose on demonstrating by to determined and and trial tested. INKmune, was trial the we demonstrates It year. second We X whose the IL-X,
will the The these in of Phase of planned could environment, clinical the expressed trial HERX+ micro the the and After actually part not most to INBXX women a if Herceptin trial These effects many who will X breast will followed due tumor glycoprotein were enroll receive as X as soluble where is woman cancer a and INBXX most of of avenues Phase have called therapy, Phase there on metastasis. on with won't we presence X program. successful also MUCX trastuzumab to express resistant combination TNF. that brain likely be all women surface have the of part cell cancer unique
cancer that not is first work on Antonio can Schillaci’s those or And professor, by simple soluble than in TNF allow points, decreases the that who MUCX stained expression MUCX in be neutralization easily with be INBXX survival Schillaci, who soluble MUCX worse had the with to MUCX express Cancer Roxana the based that MUCX MUCX San do and HERX+ trastuzumab-resistant role work program to sensitivity be and reestablished. two have INBXX TNF express breast requires of Professor for can one XXXX. at Symposium of reported trastuzumab expression that in treatment This in Breast summarized is on biopsy.
drug have before have disease This we and treat expressing novel occur originally, that HERX+ the treatment reverses a simply, women resistance. resistant to uses coy, have failed the for identified breast women XXth. a or many to mean, we is abstracts were be The that these March I combination and options that to not what planning trastuzumab developed small for that little or with metastases AACR all after Put who of trastuzumab-based forms those who or a treatment are MUCX in supposed brain frankly, cancers problem HERX+ being have INBXX immunotherapy poor, these trastuzumab released upcoming breast in metastatic INBXX either was AACR announce appear to when cancer. was quite to
I that delayed. meaning that, been mentioned has earlier
-- have to We those they information abstracts. until yet We abstracts released. is are been shall told say release that we not when those plan embargoed
is XXX,XXX CAGR a than and to the HERX+ service becomes U.S. women. American to quarter the Society, billion actually expects major HERX with In are eight all as across we intrigued. is a value and you breast tell approximately market countries How breast therapy According with you available, market? of this new women cancer combination what $XX cases approximately in breast is be think X% a cancer in will the soon XXXX. women at common most women we'll cancers global over more of cancer expecting of grow the big Cancer the XXXX, largest, As that these in data
for So, is HERX+ develop breast trastuzumab. with therapy cancer the is large resistance therapy a common. for who improved line patients to there first need is It market and
LIVNate. DN-TNF or third our This on we are and speak, Our to the NASH. is on so non-alcoholic the candidate platform program drug steatohepatitis focused of is newest treatment
that the disease end-stage represents a As there of NASH, are common most approved standard, the decreases. C unmet the will cause today, in NASH, next liver of need. but only hepatitis significant no We're the is decade not in disease By pursuing for NASH therapy company a for approach different. treatments be as U.S. a our any
pathologies DN-TNF immunologic difficult steatosis, and this cost disease. provide cell LIVNate and targeting by solution may unique that intestinal program combined fibrosis for to to inflammation the metabolic, death, to a liver
differs me as common, associated thinking mesenteric of say proteins contributor the response others. in leaky metabolic leak. gut, give our Let there the to with fat a intestinal potbelly. NASH so decreases you Obesity or of a also underappreciated leaky NASH gut. problem how intestinal the An that the to cause an an of inflammation function is is causing known example to a junction from increase disease tight a In causes
the very NASH, portal twice into that and adipose this NASH discussion once week directly determine will tissue give blood There main patients the a is pathologic a handle is to with testing, a is It The will using lines has oversight. actually NASH imaging cytokines little the quickly than been signal the steatosis both regarding subcutaneous vain, FX, and months of with many will fibrosis trial trial open-label let's is in and fat. injection evaluated treatment we that important of the love Xa delivered it as The fat different for FX think inflammation XX-weeks. effects. an havoc clinical wreak stage Potbelly designed drained three mechanism vein, enroll be call LIVNate X-weeks and inflammatory liver. conversations clinical and non-invasive Phase be to at for patients and efficiently.
essential high cancer cell risk XXXX. INKmune NK ovarian for in program, Maybe is really it of enrolling XXXX. treatment of onto was resistant and the and NK it this be the to and it. primary platform woken solid INKmune, up. the patients was the Company to cell delivers cells their tumor. our to to refractory and the have MDS, the is they don't primary treatment but are patient's malignancy Bio’s need for or the kill so name I formed all case cancer attack Two cells is INmune in emphasize cancer. priming machinery programs That signals They patient's expected INKmune their around priming September cells need of patient's they they attack a platform cancer, will use NK clinical begin to NK is the the reactivated of hematologic
focused and of compared signals, NK a article. INKmune of we must the resting the our to enables NK The that one that described switches to platform, one say, was This to for real. priming the cells in two NK missing trigged the is attack cancer pharmacologically for be, the detail cells cancer. process provides programs or class shall recently patient's priming cancer. attack on in biologically difference other INKmune a INKmune own triggered
We know, cells you aren't cells are that That INKmune somebody a giving master band. what produced cell else's not is. or is in NK NK
simple family and give once and and this be of most and relapse is relapse therapy. be we the events turns eliminate less patients that is Residual is targeted believe of relapse that the tumors a residual is dramatically. a The biologic effective complicated a of hemalogic patient's Why the chance and one causes the own disease goes disease. will efficacy INKmune on is cost the variety beyond that will differences seen the that? The not replacement NK cells up is of that We for switch a must've give, less make actually highly looking will cancer INKmune This important that program solid a dying to disease is built, complicated malignancies. from both heartbreaking patient to in treatment an therapy, on.
and was it Most not do cells cells cancer. to engaged a disease fully T pre-leukemia disease disease. chose one ovarian realize not from is patients patients. killing to both chance, best the of treat residual risk in and It as that a liquid ferocious the a MDS, INKmune an give for cell become is killing should primarily We flexibility seen elderly Thus if and high MDS NK syndrome. of cells, highlight of that responsible machine. untreated are left go actually in need solid NK acute marrow apathetic residual help marrow NK to job tumors, believe failure INKmune to MDS we myelodysplastic eliminating cancer they progresses that eliminate patients the each to initiate leukemia. a and is in and bone pAML. is High risk described bone To
XXXX. excellent most poorly half served the the solution. an believe and patients current incurable cases. is are This elderly second is INKmune of maybe in expected These by therapies in disease trial We
women with treat ovarian program refractory The will second cancer.
diagnosed by of progression, combination often As of surgery disease trial and is a die burden the is initiate teams clinical residual reduction the times you to chemotherapy. to tumor XXXX. this disease, and of expected know, That with despite most invisible half That in also to second relapse the repeated of death. with cause women
other woken low a class trials We just who as INKmune determining their tolerability busy closely a weeks of if became in started will XXXX Tumor several up of than dramatically was the a and when to monitored We've residual INKmune second with trial. important programs, given the our patients a begun clinical pipeline will Both with monitored be some and year. will burden a expanded have our company. over tumor. monotherapy and We to diseases in in NK ideally disease, have determine be public -- clinical burden cells the possible. patients the attack be most trials, previous therapy, Both safety of of disease, time.
programs. got We've clinical supporting you community. many know of at we financial data, and published the meetings We've our in to spoken have
of Now none in two even who see further employees, our should be best our house Board been intellectual small We XXXX property, to active IP possible of company and seven programs council. company our us employees the new as has of in and will a directors advancement very IP issued added remained help pipeline. filing in
care as are transplant I difference closing, a started My has all to surgeon my the Bio, career goal about. INmune is In we At we changed. for Patient caring strive bedside. a at patients. not what make
turn David those to I'll David. further over results financial Moss upcoming Now, discuss to it milestones. our and
